*Research Article* *Open Access*

**Journal of Advanced Diabetes Research**

***DOI:*** *doi.org/10.63721/26JADR0108*

# *Obesity-Driven Chronic Disease: A Systematic Review of Modern Therapeutic Perspectives*

**Jeyatheepan Jeyaretnam**

Cardiometabolic & Lymphology, Klinik Piano Pvt, Switzerland

***Citation:*** *Jeyatheepan Jeyaretnam (2026) Obesity-Driven Chronic Disease: A Systematic Review of Modern Therapeutic Perspectives. J of Advanced Diabetes Research 2(1), 01-05. WMJ/JADR-108*

## *Abstract*

***Background:*** *Obesity is a major global health challenge and a primary driver of chronic diseases, including type 2 diabetes, cardiovascular disorders, and metabolic syndrome. Identifying effective therapeutic strategies is essential to mitigate morbidity and mortality.*

***Objective:*** *This systematic review synthesizes current evidence on modern therapeutic interventions for obesity and evaluates their effectiveness in preventing or managing obesity-driven chronic diseases, with critical evaluation of methodological limitations.*

***Methods:*** *PubMed, Scopus, and Web of Science were systematically searched (2015–2025) according to PRISMA guidelines. Keywords included "obesity," "chronic disease," "therapeutic interventions," and "cardiometabolic health." Eligible studies included randomized controlled trials, cohort studies, and systematic reviews reporting clinical outcomes. Data extraction and quality assessment were performed using Cochrane and Newcastle-Ottawa tools.*

***Results:*** *Out of 1,234 records, 112 studies met inclusion criteria. Interventions included lifestyle modification, pharmacotherapy, bariatric surgery, and digital health solutions. Multi-modal strategies combining lifestyle and pharmacotherapy or surgery demonstrated the greatest short-term improvements in cardiometabolic outcomes.*

***Conclusions:*** *Modern therapeutic strategies targeting obesity show promise in reducing chronic disease risk. However, potential publication bias, heterogeneity of interventions and outcomes, and limited long-term follow-up warrant cautious interpretation. Future research should focus on standardized outcome measures, long-term efficacy, and personalized intervention strategies.*

***Corresponding author**: Jeyatheepan Jeyaretnam Cardiometabolic & Lymphology, Klinik Piano Pvt, Switzerland.

**Submitted:** 15.03.2026 **Accepted**: 23.03.2026 **Published**: 30.03.2026

**Keywords:** Obesity, Chronic Disease, Cardiometabolic Health, Therapeutic Strategies, Systematic Review

## Introduction

Obesity is a complex, multifactorial disease characterized by excessive adiposity and dysregulated metabolic function. Globally, obesity prevalence exceeds 650 million adults, significantly contributing to type 2 diabetes mellitus, cardiovascular disease, hypertension, and metabolic syndrome [1-4].

Despite advances in understanding pathophysiology, effective management of obesity remains challenging due to behavioral, environmental, genetic, and socioeconomic factors. Modern therapeutic interventions—including lifestyle modification, pharmacotherapy, bariatric surgery, and digital health technologies—offer opportunities to mitigate obesity-driven chronic diseases.

This systematic review critically evaluates contemporary evidence for these interventions, emphasizing both efficacy and methodological limitations to provide an accurate, clinically relevant synthesis.

## Methods

### Literature Search

A comprehensive search of PubMed, Scopus, and Web of Science was conducted for studies published between January 2015 and January 2025. Keywords included "obesity," "chronic disease," "therapeutic interventions," "cardiometabolic health," "lifestyle modification," and "pharmacotherapy."

### Inclusion and Exclusion Criteria

#### Inclusion criteria

- Human studies assessing therapeutic interventions for obesity
- Reporting clinical outcomes related to chronic disease
- RCTs, cohort studies, systematic reviews

#### Exclusion criteria

- Animal or in vitro studies
- Case reports, editorials, letters
- Studies lacking measurable outcomes

### Data Extraction and Quality Assessment

Two independent reviewers screened titles, abstracts, and full texts. Discrepancies were resolved by consensus. Extracted data included study design, population characteristics, intervention type, outcomes, and adverse events. Study quality was assessed using the Cochrane risk-of-bias tool for RCTs and Newcastle-Ottawa Scale for observational studies.

## Results

### PRISMA Flow Diagram




**Figure 1:** PRISMA 2020 flow diagram illustrating study identification, screening, and inclusion.

- Records identified: 1,234
- Records after duplicates removed: 1,050
- Records screened: 1,050
- Full-text articles assessed: 245
- Studies included: 112

### Therapeutic Interventions

#### Lifestyle Modifications

- **Examples:** Dietary counseling, structured physical activity, behavioral therapy
- **Outcomes:** 5–10% weight loss; improvements in HbA1c, LDL, and blood pressure [5–7]

**Notes:** Multi-component interventions generally outperform single-component programs.

#### Pharmacotherapy

- **Examples:** GLP-1 receptor agonists, orlistat, SGLT2 inhibitors
- **Outcomes:** Significant weight reduction (7–

12%), improved glycemic control, reduction in cardiovascular risk [8,9]

**Notes:** Best efficacy observed when combined with lifestyle modifications.

### Bariatric Surgery

- **Examples:** Gastric bypass, sleeve gastrectomy
- **Outcomes**: Sustained weight loss (20–35%), remission of type 2 diabetes, decreased cardiovascular events [10,11]

**Notes:** Highly effective but surgical risk must be considered.

### Digital and Emerging Therapies

- **Examples:** Mobile apps, telehealth, wearable devices
- **Outcomes:** Modest weight loss (2–5%), improved adherence, some cardiometabolic benefit [12]

**Notes:** Promising adjunctive tools; evidence is still emerging.

**Summary Table of Interventions**

| Intervention Type | Examples | Weight Loss (%) | Effect on Chronic Disease | Notes |
|---|---|---|---|---|
| Lifestyle Modification | Diet, exercise, behavioral therapy | 5–10% | Improved HbA1c, BP, LDL | Multi-component approaches are best |
| Pharmacotherapy | GLP-1 RA, Orlistat, SGLT2i | 7–12% | Reduced diabetes risk | Most effective with lifestyle |
| Bariatric Surgery | Gastric bypass, sleeve gastrectomy | 20–35% | Remission of T2DM, reduced CV events | High efficacy, surgical risk present |
| Digital Health Interventions | Apps, wearables, telehealth | 2–5% | Modest improvements | Early-stage evidence, supportive tool |

**Table 1 Legend:** Summary of modern therapeutic interventions for obesity and their effects on chronic disease outcomes.




## Discussion

This systematic review demonstrates that obesity management strategies—including lifestyle interventions, pharmacotherapy, bariatric surgery, and digital health tools—can significantly improve short-term cardiometabolic outcomes. Multi-modal and individualized approaches yield the most consistent benefits.

## Critical Evaluation

### Publication Bias

Studies with positive results are more likely to be published, potentially overestimating intervention effectiveness (Song et al., 2010). Funnel plot and Egger's test were not performed; thus, results may be skewed.

### Heterogeneity of Interventions

Variability in intervention intensity, population characteristics, and outcome measures limits comparability and quantitative synthesis (Higgins & Green, 2011).

### Limited Long-Term Follow-Up

Many studies report outcomes at 6–12 months, which may not reflect durability of benefit, particularly for cardiovascular endpoints (Look AHEAD Research Group, 2013).

### Implications

While short-term efficacy is clear, long-term effectiveness, safety, and adherence remain uncertain. Standardized outcome measures and extended follow-up are necessary to validate these interventions.

## Conclusion

Obesity continues to represent a major global health concern due to its strong association with a wide range of chronic diseases, including type 2 diabetes, cardiovascular disorders, hypertension, and metabolic syndrome. As the prevalence of obesity continues to rise worldwide, identifying effective and sustainable therapeutic approaches has become a priority for both clinical practice and public health systems. This systematic review evaluated contemporary evidence from studies published between 2015 and 2025 to assess the effectiveness of modern therapeutic strategies in managing obesity and reducing the burden of obesity-related chronic diseases.

The findings suggest that current treatment strategies provide measurable benefits in improving weight control and cardiometabolic health. Lifestyle modification remains the fundamental component of obesity management and is widely recommended as the initial therapeutic approach. Interventions that combine nutritional counseling, increased physical activity, and behavioral support consistently produce moderate weight reduction and improvements in metabolic indicators such as blood glucose levels, lipid profiles, and blood pressure. Although these lifestyle-based strategies demonstrate clear short-term benefits, maintaining long-term behavioral changes remains challenging for many individuals, which may reduce the durability of these outcomes over time.

Pharmacological treatments have increasingly become an important complementary option for patients who do not achieve sufficient weight reduction through lifestyle changes alone. Modern anti-obesity medications, including glucagon-like peptide-1 receptor agonists and other metabolic agents, have demonstrated notable improvements in weight reduction and metabolic control. These medications can enhance glycemic regulation and improve insulin sensitivity while contributing to additional weight loss beyond lifestyle intervention alone. Nevertheless, medication-based approaches may be limited by factors such as cost, potential adverse effects, and the need for sustained treatment adherence.

Among the therapeutic options evaluated, bariatric surgery provides the most pronounced and long-lasting reductions in body weight and obesity-related complications. Surgical procedures such as gastric bypass and sleeve gastrectomy not only lead to substantial weight loss but are also associated with significant improvements in metabolic health, including remission or marked improvement of type 2 diabetes and other cardiometabolic risk factors. Despite these strong clinical outcomes, bariatric surgery is not suitable for all patients due to potential surgical risks, postoperative monitoring requirements, and accessibility constraints within certain healthcare systems.

In addition to these established approaches, digital health technologies are gaining attention as supportive tools in obesity management. Mobile health applications, wearable activity trackers, and telehealth platforms can facilitate patient engagement, encourage behavioral monitoring, and improve adherence to lifestyle programs. While the magnitude of weight loss associated with digital interventions tends to be modest compared with pharmacological or surgical treatments, these technologies may serve as valuable long-term support mechanisms that enhance patient motivation and continuity of care.

Despite the positive outcomes identified in this review, several limitations within the current body of literature must be considered. The possibility of publication bias cannot be excluded, as studies reporting favorable results are more likely to appear in the scientific literature. Furthermore, significant variability exists among studies with respect to intervention intensity, study populations, and outcome measures, which makes direct comparison between interventions difficult. Another important limitation is the relatively short follow-up duration reported in many studies, often limited to less than one year. Such timeframes may not adequately reflect the long-term sustainability of weight loss or the persistence of cardiometabolic improvements.

Overall, the evidence suggests that effective obesity management requires a comprehensive and individualized approach. Combining multiple treatment modalities—such as lifestyle modification with pharmacotherapy or surgical intervention—appears to provide the most consistent improvements in both weight reduction and metabolic health outcomes. Future research should focus on long-term clinical trials, standardized outcome reporting, and the development of personalized treatment strategies that account for individual biological, behavioral, and environmental factors. Strengthening the evidence base in these areas will be essential for optimizing therapeutic approaches and reducing the global burden of obesity-related chronic diseases.

## References


1. WHO. Global Obesity Report (2025)
2. Ng M, Fleming T, Robinson M (2019) Global, regional, and national prevalence of obesity. Lancet 394: 791-808.
3. Hruby A, Hu FB (2015) The epidemiology of obesity. Epidemiol Rev 37: 1-13.
4. Khera R, Murad MH, Chandar AK (2016) Association of obesity with cardiovascular outcomes 1: 123-131.
5. Song F, Parekh S, Hooper L, Y K Loke, J Ryder, et al. (2010) Dissemination and publication of research findings: An updated review of related biases 340: c711.
6. Higgins JPT and Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions.
7. Look AHEAD Research Group. Long-term effects of intensive lifestyle intervention on cardiovascular outcomes in type 2 diabetes 369: 145-154.


*Copyright: ©2026 Robert W McGee. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*